Navigation Links
Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
Date:10/23/2008

KENILWORTH, N.J., Oct. 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that its novel psychopharmacologic agent asenapine has met the primary endpoint in a long-term schizophrenia relapse prevention trial. Asenapine, which is administered as a fast-dissolving sublingual tablet, is a psychopharmacologic compound with a unique human receptor signature.

The study was a randomized, placebo-controlled, double-blind, multicenter, multinational clinical trial evaluating the efficacy and safety of sublingually administered asenapine (5 or 10 mg BID) compared to placebo in the prevention of relapse in subjects with schizophrenia. A total of 700 subjects entered the open-label treatment with asenapine for up to 26 weeks. Of these, a total of 386 subjects met criteria for stabilization on asenapine and were randomized to treatment in the 26-week double-blind placebo-controlled phase of the trial.

Asenapine was statistically significantly more effective than placebo in preventing relapse, the primary endpoint of the trial. Asenapine was generally well tolerated during the trial. Full results of the trial, including efficacy, safety and tolerability data will be presented at a later date. These data are planned to be used to support a regulatory submission for the approval of asenapine in Europe.

Schering-Plough acquired asenapine in November 2007 through its acquisition of Organon BioSciences, which developed the product. Asenapine is currently under review by the U.S. Food and Drug Administration for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder.

Schering-Plough is an innovation-driven, science-centered global health care company. Th
'/>"/>

SOURCE Schering-Plough
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
2. World Think Tank on Type 1 Diabetes Meets in Miami
3. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
4. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
5. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
6. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
7. The Science of Music Meets the Art of Medicine - ARIMM 3rd Annual Conference at IPFW, September 12-13, 2008
8. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
9. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
10. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Graphite Metallizing Corporation announces a ... in stainless steel pillow blocks. This series combines ... the application and installation versatility of pillow blocks. ... work exceptionally well when submerged in water, water-soluble ... as acids, alkalies, hydrocarbons, black liquor, and liquid ...
(Date:5/23/2013)...  Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., ... banking and therapeutics, announced today that StemCyte has become ... Indy car driven by James Jakes ... IndyCar 2013 season.   StemCyte, Inc. and Rahal ... of umbilical cord blood banking and its educational initiative ...
(Date:5/23/2013)... SAN MARINO, Calif. , May 23, 2013 ... announces today a strategic alliance with DAK Renewable ... increase the corn oil yield. VG Energy is ... Inc. (OTC Pink: VGLS). VG Energy,s ... pathways to increase the oil yield in plants, ...
(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...
Breaking Biology Technology:Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... Cardium Health, AirLogix, and Work/Life Innovations into Next Generation ... ... Company, BEDFORD, Mass., March 4 CaseNET, Inc., a provider ... of Centene Corporation (NYSE: CNC ), has selected,the CaseNET platform ...
... - Two new independent non-executive directors added to Board with ... ... Eutick, OAM appointed independent non-executive Chairman, BRISBANE, Australia, March ... the,appointment of John Lee and Robert Williamson to the Company,s ...
... SOUTH SAN FRANCISCO, Calif., March 4 Sunesis,Pharmaceuticals, ... developing novel anticancer therapeutics, will present data at ... by the Society of,Gynecologic Oncologists (SGO). This year,s ... Tampa Convention Center in Tampa, Fla., Interim ...
Cached Biology Technology:Nurtur(TM) Selects CaseNET to Enable Integrated Health and Life Management Capabilities 2Progen Expands Board of Directors 2Progen Expands Board of Directors 3Progen Expands Board of Directors 4Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Women's Cancer 2
(Date:5/22/2013)... May 22, 2013. Plastic additives known as phthalates ... everywhere: They turn up in flooring, plastic cups, ... the Centers for Disease Control and Preventionthe bodies ... have come under increasing scrutiny. A growing collection ... can leech from packaging and mix with food) ...
(Date:5/21/2013)... concept of "place" is increasingly being considered in ... have a new resource that can help them ... with the places in their lives. , ... new book co-edited by the Pacific Northwest Research ... human-centered approach to conservation. The book is published ...
(Date:5/21/2013)... USC have found that a class of pharmaceuticals can ... , The drugs, known as "TSPO ligands," are currently ... at the effects of TSPO ligand in young adult ... in aged mice when pathology was quite severe," said ... of Gerontology. "TSPO ligand reduced measures of pathology and ...
Breaking Biology News(10 mins):Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Drugs found to both prevent and treat Alzheimer's disease in mice 2
... antibody targeting a well known cell surface protein inhibited ... of the disease that did not respond to hormone ... UCLA Department of Urology and UCLA,s Jonsson Comprehensive Cancer ... N-cadherin, is up regulated or turned on in prostate ...
... This release is available in French . , Frank ... table would make people more aggressive, not less. After all, dont ... a game in hopes of pumping them up? And what about ... who dares take their meat away from them? Wouldnt that go ...
... Miss. A summit that,s both scientific conference and ... front lines of fighting obesity and related metabolic diseases ... sponsored by the University of Mississippi Medical Center and ... the Jackson Convention Complex. Obesity and related ...
Cached Biology News:UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 2UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 3Caveman behavioral traits might kick in at Thanksgiving table before eating 2Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 2Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 3Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 4Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 5
Applications: Western blotting ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
... 100 Amplification Kit, 100 reactions. Prepare ... in 4-6 h.Generate microgram quantities of ... starting material.Use amplified DNA directly for ... bacterial or M13 liquid cultures, colonies, ...
Biology Products: